Lymphoma,MZL (Marginal Zone Lymphoma) Rituximab Plus Ibrutinib Show Efficacy and Safety in Untreated MZL Aug 18, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Axi-cel as a Second-line Therapy for LBCL Pts-Ineligible for HDCT/HSCT Aug 17, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Consolidative HCT-ASCT Improves PFS In Newly-Diagnosed PCNSL Aug 16, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma ctDNA as a Noninvasive Biomarker in High-Risk LBCL Aug 16, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Axi-Cel Versus SOC in Patients With Early R/R LBCL Aug 11, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma REMoDL-B Phase 3 Study: Evaluation of Molecular Guided Therapy for DLBCL Apr 20, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Residual Disease Kinetics in High-Risk CLL Patients: Ibr+Ven vs Clb+O Mar 23, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Real-World Comparison of ACP-196 and Ibrutinib in CLL Treatment Mar 23, 2023